Heparin in malignant glioma: review of preclinical studies and clinical results

Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

(2014) Thangirala Sudha et al.   CANCER LETTERS

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials

(2014) D. Sanford et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Oncogenes and the coagulation system – forces that modulate dormant and aggressive states in cancer

(2014) Nathalie Magnus et al.   THROMBOSIS RESEARCH

The efficacy and safety of low-molecular-weight heparin use for cancer treatment: A meta-analysis

(2013) D.H. Che et al.   European Journal of Internal Medicine

Heparin blocks transfer of extracellular vesicles between donor and recipient cells

(2013) Nadia A. Atai et al.   JOURNAL OF NEURO-ONCOLOGY

Coagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype

(2013) N. Magnus et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Differential Adeno-Associated Virus Serotype-Specific Interaction Patterns with Synthetic Heparins and Other Glycans

(2013) M. Mietzsch et al.   JOURNAL OF VIROLOGY

Extracellular vesicles: biology and emerging therapeutic opportunities

(2013) Samir EL Andaloussi et al.   NATURE REVIEWS DRUG DISCOVERY

Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity

(2013) H. C. Christianson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role

(2013) Alessandro Puppa et al.   THROMBOSIS AND HAEMOSTASIS

ScFv Anti-Heparan Sulfate Antibodies Unexpectedly Activate Endothelial and Cancer Cells through p38 MAPK: Implications for Antibody-Based Targeting of Heparan Sulfate Proteoglycans in Cancer

(2012) Helena C. Christianson et al.   PLoS One

Oncogenic extracellular vesicles in brain tumor progression

(2012) Esterina D’Asti et al.   Frontiers in Physiology

M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis

(2011) He Zhou et al.   PLoS One

Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2–mediated heparin-binding EGF signaling in endothelial cells

(2011) Katrin J. Svensson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma

(2010) J. R. PERRY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Repeated hepatocyte growth factor neutralizing antibody treatment leads to HGF/SF unresponsiveness in human glioblastoma multiforme cells

(2009) Ping Zhao et al.   CANCER LETTERS

Targeted drug delivery for treatment and imaging of glioblastoma multiforme

(2009) Jill M Stukel et al.   Expert Opinion on Drug Delivery

Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival

(2009) Nicole M. Kuderer et al.   JOURNAL OF CLINICAL ONCOLOGY

Directed evolution of adeno-associated virus for glioma cell transduction

(2009) Casey A. Maguire et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Heparin as an anticancer therapeutic

(2008) Leo R Zacharski et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells

(2008) Khalid Al-Nedawi et al.   NATURE CELL BIOLOGY

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

(2008) Johan Skog et al.   NATURE CELL BIOLOGY